Search filters

List of works by Siwen Hu-Lieskovan

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

scientific article published oln 16 November 2016

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

scientific article published on 01 October 2020

A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

scientific article published on 20 December 2018

A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results

scientific article

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

scientific article

Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations

scientific article published on 4 November 2015

Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial

scientific article published on 01 July 2019

Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration

scientific article published on 25 October 2021

Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges

scientific article published on 01 May 2020

Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?

scientific article published on 25 September 2019

Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1

scientific article published on 17 November 2020

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

scientific article published on 17 August 2015

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges

scientific article

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

scientific article published on 06 February 2016

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer

scientific article published on 05 September 2019

EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients

scientific article

EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors

scientific article published on June 2005

Excluding T Cells: Is β-Catenin the Full Story?

scientific article published in June 2015

Exosomes as a predictor tool of acquired resistance to melanoma treatment

scientific article published in October 2014

Genetic mechanisms of immune evasion in colorectal cancer

scientific article published on 6 March 2018

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

scientific article published on 15 March 2016

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

scientific article published on 01 January 2017

High response rate to PD-1 blockade in desmoplastic melanomas

scientific article published on 10 January 2018

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

scientific article published on 15 April 2019

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

scientific article published on March 2015

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

scientific article published on 5 May 2015

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure.

scientific article published on 4 November 2015

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

scientific article published on 01 December 2019

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

scientific article published in May 2017

Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules

article published in the Proceedings of the National Academy of Sciences of the United States of America

Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

scientific article published on 01 January 2019

Mechanisms of Resistance to PD-1 Checkpoint Blockade

scientific article published on 01 April 2020

Mechanisms of Resistance to PD-1 and PD-L1 Blockade.

scientific article published in January 2018

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

scientific article published on 13 July 2016

New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone

scientific article published in January 2017

Overcoming genetically-based resistance mechanisms to PD-1 blockade

scientific article published on 28 May 2020

PAK4 inhibition improves PD-1 blockade immunotherapy

scientific article published on 09 December 2019

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

scientific article published on 31 January 2020

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

scientific article published on 20 June 2017

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

scientific article published on 30 November 2016

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

scientific article published on February 2017

Proceedings of the 2016 China Cancer Immunotherapy Workshop: Beijing, China. 25-26 June 2016.

scientific article published on 13 October 2016

Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit

scientific article published on 29 July 2020

Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab

scientific article published on 02 November 2019

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells

scientific article published on 2 September 2016

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery

scientific article published on 01 December 2020

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis

scholarly article by Clint T Allen et al published 3 May 2019 in Journal for Immunotherapy of Cancer

Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma

scientific article published on October 2005

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer

scientific article published on 21 May 2019

What does PD-L1 positive or negative mean?

scientific article

Paulina is supported by:

About Paulina

Help